Verastem Trumpets Early Clinical Results For FAK Program, Discloses Timelines And Plans
This article was originally published in The Pink Sheet Daily
Executive Summary
Addressing an audience of 150 attendees at its first clinical-stage R&D day on July 11, Verastem Inc. put forward its new senior executive team, as well as an eminent authority in cancer stem cell biology, to describe its clinical progress thus far, and its future plans.
You may also be interested in...
Verastem Catapults To Mid-stage Development with Pfizer Licensing Deal
The Massachusetts-based cancer stem cell company has struck two deals in as many days in an effort to move compounds into the clinic for various types of cancers and multiple targets.
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.